MétaCan
Menu
Back to cohort
Record W3101468130

Investigating the use of circulating tumor DNA for cancer surveillance and early detection in (pediatric) sarcomas and Li-Fraumeni Syndrome

2020· dissertation· en· W3101468130 on OpenAlexaboutno aff
Sangeetha Paramathas

Bibliographic record

VenueTSpace · 2020
Typedissertation
Languageen
FieldMedicine
TopicSarcoma Diagnosis and Treatment
Canadian institutionsnot available
Fundersnot available
KeywordsLi–Fraumeni syndromeCancerMedicineOncologyCancer researchInternal medicineGeneticsBiologyGeneMutationGermline mutation
DOInot available

Abstract

fetched live from OpenAlex

Circulating tumor DNA (ctDNA) is a biomarker that has been shown to be valuable in a variety of contexts in clinical oncology such as determining prognosis, monitoring treatment and predicting recurrence. Early detection using ctDNA may be invaluable for patients with a genetic risk to develop cancers. Li-Fraumeni Syndrome (LFS) is a cancer predisposition syndrome caused by inherited mutations in the tumor suppressor gene, TP53. LFS is characterized by early onset of a wide spectrum of tumors and an 83-fold lifetime risk of multiple cancers. The 'Toronto Protocol' is a multi-modality clinical surveillance protocol that was developed to facilitate early cancer detection in this population. The protocol utilizes a combination of MRI scans, ultrasounds, biochemical tests, and physical examinations. Though it has been shown to be effective in reducing tumor related mortality and treatment related morbidity, reduced sensitivity and specificity make clinical surveillance challenging to implement. To address these challenges, we are using a combination of xenograft and spontaneous tumor forming animal models to study the dynamics of ctDNA in relation to tumor burden and to resolve the feasibility of capturing the development of tumors at their earliest stages. Our work using a rhabdomyosarcoma xenograft model demonstrated that there is a strong relationship between tumor burden and ctDNA concentration in the blood. Furthermore, we detected ctDNA during the development of small, early lesions using simulated metastasis models. In a follow-up study, we used a Trp53R172H/+ pre-clinical model of LFS to assess the use of ctDNA as a surveillance tool for early detection of spontaneously developing tumors. We were able to identify ctDNA in blood samples collected before and at the onset of tumor formation as confirmed by radiological imaging and subsequently used ctDNA to monitor cancer progression. Our studies provide the first evidence demonstrating the capacity of circulating tumor DNA for early cancer detection in pediatric sarcomas, specifically arising from a hereditary cancer predisposition syndrome. Given the spontaneous nature of tumor formation in LFS, the benefits of early cancer detection and subsequent diagnosis are unparalleled in this patient population by accelerating introduction of early treatment intervention and improving disease prognosis. This work illustrates the capacity for ctDNA detection to complement and enhance cancer surveillance protocols in LFS patients. Furthermore, the outcomes of this study will support the validation and implementation of ctDNA analysis for cancer surveillance in the clinic.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.003
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.007

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.003
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.051
GPT teacher head0.320
Teacher spread0.269 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueTSpaceSame topicSarcoma Diagnosis and TreatmentFrench-language works237,207